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Tropical Journal  of Pharmaceutical Research is ind exed by Science Citation Index ( Purpose: Toformulate 
glutaraldehyde-cross-linked chitosan-based microparticles and evaluate its suitability for the delivery of 
ibuprofen, a BCS class II drug. 
Methods: Ibuprofen-loaded chitosan microparticles were prepared by emulsification-cross-linking 
technique using glutaraldehyde saturated toluene (GST) as the cross-linking agent. The microparticles 
were characterized with respect to morphology, particle size, microparticle yield and entrapment 
efficiency. The swelling behaviour of the particles and ibuprofen release were assessed in both 
simulated gastric fluid (SGF) without pepsin (pH 1.2) and simulated intestinal fluid (SIF) without 
pancreatin (pH 7.4).  
Results: Discrete and free-flowing microparticles of size range 100.05 ± 8.82 to 326.70 ± 10.43 µm 
were obtained. The microparticles had a high yield (69.2 to 99.2 %) and exhibited greater water sorption 
capacity in SIF (122.2 %) than in SGF (60 %). Furthermore, the microparticles cross-linked with 10 ml of 
GST entrapped the highest amount of drug (23.32 ± 0.97 %) while those cross-linked with 25 ml GST 
had the highest yield of the microparticles (99.19 % ), and highest water sorption in SIF (122.2 %). Up to 
93.6 % of the entrapped drug was released in SIF from microparticles cross-linked with 25 ml of GST. 
Drug release from microparticles cross-linked with 20 and 30 ml each of GST showed a biphasic 
pattern.  
Conclusions: Entrapment of ibuprofen in glutaraldehyde-cross-linked chitosan microparticles can be 
exploited to target and control the release of the drug and possibly reduce its gastro-erosive side 
effects. 
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The efficacy of a drug can be markedly 
influenced by the method by which the drug is 
delivered. There is growing interest and 
investment in the use of polymer-based systems 
in drug discovery and product development to 
effectively overcome problems related to stability 
and bioavailability [1,2]. Microparticulate carrier 
systems made from naturally occurring 
biodegradable and bioadhesive (mucoadhesive) 
polymers have attracted considerable attention 
over the years [3].  
 
Chitosan (obtained by deacetylation of chitin) is a 
naturally occurring cationic polymer which finds a 
wide array of applications due to its low 
production costs, biodegradability, biocompa-
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tibility, nontoxic nature and mucoadhesion [4]. 
Microspheres prepared with chitosan by various 
methods have been used for the controlled 
release of many drugs, among other applications 
[4,5]. Factors affecting the release of drug from 
chitosan microspheres include the molecular 
weight and concentration of chitosan, the cross-
linking agent used and its concentration, process 
variables like stirring speed, type of oil, additives, 
cross-linking process used, drug-chitosan ratio 
etc.  
 
Application of non-steroidal anti-inflammatory 
drugs (NSAIDs) in therapy is fraught with a 
myriad of draw-backs especially gastrointestinal 
side effects. Ibuprofen is a NSAID that is often 
used orally to relieve inflammation, fever and 
pain. A number of reports have focused on 
controlling the release of ibuprofen, with some 
level of success, by entrapping it in 
microcapsules based on mucoadhesive polymers 
including sodium alginate, methylcellulose, 
ethylcellulose, hydroxypropylmethylcellulose and 
sodiumcarboxymethylcellulose, either in 
combination or singly [6,7]. Glutaraldehyde 
cross-linked chitosan has been used by earlier 
investigators to achieve a controlled release of 
diclofenac sodium and as a long acting 
biodegradable delivery vehicle for mitoxantrone 
[8-10]. In those earlier reports, it was shown that 
drug diffusion from a chitosan matrix could be 
effectively controlled by cross-linking the matrix 
using a dialdehyde such as glutaraldehyde. It is 
in this vein that we set out in the present study to 
entrap ibuprofen in glutaraldehyde cross-linked 
chitosan microparticles with a view to controlling 
its release.  
 
Consequently, the aim of the present 
investigation was to explore the potential 
applications of microparticles based on medium-
molecular-weight chitosan cross-linked with 
glutaraldehyde for the controlled delivery of 
ibuprofen with a long-term objective of achieving 
a reduction in the gastro-erosive side effects of 






Ibuprofen (BASF, Germany), chitosan low 
viscous (Sigma-Aldrich, USA), acetone, 
concentrated hydrochloric acid, glutaraldehyde, 
sodium chloride (BDH, England), sodium 
hydroxide, Span 80 and toluene (Merck, 
Germany); monobasic potassium phosphate 
(Sigma Chemical Co., USA), petroleum ether 
(Fluka, Germany), liquid paraffin (May and 
Baker, England) were used as procured from the 
manufacturers without further purification. All 
other reagents were analytical grade and used 
as such. Distilled water was obtained from an all-
glass distillation apparatus. 
 
Preparation of glutaraldehyde saturated 
toluene (GST) 
 
Glutaraldehyde (100 ml) and toluene (100 ml) 
were placed in a beaker and stirred at 1000 rpm 
for 1 h using a magnetic stirrer (Remi 
Instruments, Mumbai, India). Then, the solvent 
mixture was kept overnight for stabilization after 
which the upper toluene layer saturated with 
glutaraldehyde was decanted and used as 
glutaraldehyde saturated toluene (GST). 
 
Preparation of chitosan microparticles 
 
The microparticles were prepared by simple 
emulsification phase separation technique. 
Chitosan was used as a polymer and was cross-
linked using glutaraldehyde saturated toluene 
(GST) as per the method described by Thanoo et 
al [9]. All the batches were formulated to contain 
ibuprofen and chitosan in the ratio of 1:2 while 
the volume of GST in each batch of the 
formulation was varied. Briefly, chitosan (2.0 g) 
was dissolved in 100 ml of 5 % v/v aqueous 
acetic acid solution. One gram of ibuprofen was 
dispersed in the polymer solution. The resultant 
mixture was extruded through a syringe (10 ml 
capacity) without a needle in 125 ml of liquid 
paraffin (heavy and light, 1:1 ratio) containing 0.5 
%v/v Span 80, and stirring was performed using 
a propeller stirrer (Remi Instruments, Mumbai, 
India) at 1000 rpm. After 15, 30, 45 and 60 min, 
GST (2.5 ml each) was added and further stirring 
was continued for 2 h. The amount of the cross-
linking agent was varied from 10 to 30 ml 
whereas the cross-linking time, stirring speed 
and the polymer-to-drug ratio were kept constant. 
Five batches of the microparticles denoted as 
GST10, GST15, GST20, GST25 and GST30 were 
formulated. Microparticles thus obtained were 
filtered and washed several times with petroleum 
ether (boiling point 20 – 40 ºC) to remove any 
traces of oil. They were finally washed with 
acetone to remove excess of GST. The 
microparticles were then dried at the ambient 
temperature of 28 ± 2 ºC for 24 h.   
 
Determination of percentage yield of 
microparticles 
 
The dried microparticles were weighed to obtain 
the yield of microparticles formulated per batch. 
The percentage (%) yield was calculated using 
the formula:  
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                ......      (1) 
 
where W1 = weight of the microparticles, W2 = 
weight of the drug added, and W3 = weight of the 
polymer and Span 80. 
 
Particle size analysis and morphological 
characteristics 
 
The particle size of the microparticles was 
determined by computerized image analysis on a 
photomicroscope (Lieca, Germany). A quantity 
(0.1 g) from each of the batches was dispersed 
in a mixture of liquid paraffin and Span 80 and 
mounted on a slide and observed under a light 
microscope. With the aid of software in the 
microscope, the projected diameters of the 
particles corresponding to the particle sizes of 
the microparticles were determined and the 
mean calculated. The particle morphologies were 





The degree of swelling of the microparticles was 
investigated separately in simulated gastric fluid 
(pH 1.2) without pepsin and simulated intestinal 
fluid (pH 7.4) without pancreatin. A dialysis 
membrane 9 cm long was activated by 
immersion in 50 ml of distilled water regulated at 
90 ºC for 1 h and thereafter washed with distilled 
water. A known weight of the microparticles was 
placed in the activated dialysis membrane which 
was tied at both ends and immersed in a beaker 
placed on a thermostated bath maintained at 37 
± 1 ºC. At 5 min intervals, the membrane was 
removed from each medium, dried with filter 
paper and weighed. The degree of swelling was 
calculated using the formula: 







H …  (2) 
where M1 = initial weight of microparticles (g), 
and M2 = final weight of microparticles.   
 
Determination of entrapment efficiency of the 
microparticles 
 
A quantity (100 mg) of the microparticles was 
placed in a beaker containing 100 ml of 
phosphate buffer (pH 7.4). The dispersion was 
vortexed repeatedly to break up the 
microparticles and cause them to discharge their 
contents completely. The solution was then 
filtered and analyzed spectrophotometrically at a 
wavelength of 272 nm using a Uv-Vis 
spectrophotometer (Jenway 6405). The drug 
concentration in each batch of the microparticles 
was calculated from a Beers’ plot previously 
determined for ibuprofen. An average of four 
determinations was taken as the mean drug 
content for each batch of microparticles. The 
drug entrapment efficiency (E) was calculated 
using the following formula:  
 
E (%) = (ADL/TDL)100   …... (3) 
 
where ADL is actual drug loading and TDL is 
theoretical drug loading 
 
In vitro drug release studies 
 
The USP XXVII paddle method was adopted in 
this study [11]. The dissolution experiment was 
performed in 500 ml of freshly prepared SIF (pH 
7.4) and SGF (pH 1.2) maintained at 37 ± 1 ºC. A 
known quantity (300 mg) from each batch of the 
microparticles was placed in the appropriate 
chamber of the release apparatus and agitated at 
50 rpm. At predetermined time intervals, 5 ml 
aliquots of the release medium were withdrawn, 
appropriately diluted and assayed 
spectrophotometrically at 272 nm. At every 
interval, 5 ml of fresh release medium was added 
to maintain a constant volume in the dissolution 
medium. The concentrations of the withdrawn 
samples were calculated with reference to the 
standard Beers’ plot. Three replicate release 
studies were performed in each case and the 
mean values were taken. 
 
Statistical data analysis 
 
Statistical data analyses were performed using 
SPSS (version 16). For batch comparisons, the 
student’s t-test was used to determine 




The particle size distribution of the microparticles 
is presented in Table 1. The mean particle size 
(n = 50) of the microparticles ranged from 100.05 
± 8.82 µm   to 326.70 ± 10.43 µm. Microparticles 
formulated with 10 ml of glutaraldehyde 
saturated toluene (batch GST10) had the smallest 
particle size while microparticles cross-linked 
with 25 ml of GST possessed the largest mean 
particle size. The photomicrographs (pictures not 
shown) showed that the microparticles had a 
brownish and spherical appearance except for 
some batches that appeared to have some 
degree of hydration and irregular shapes, 
especially those cross-linked with 25 ml and 30 
ml GST.  
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Volume of cross -




efficiency  a,b 
 
Size ( µm) a,c 
GST10 10 98.53 23.32 ± 0.97 100.05 ±  8.82 
GST15 15 69.27 20.67 ± 3.11 326.70 ± 10.43 
GST20 20 84.43 19.78 ± 1.06 116.72 ±  9.16 
GST25 25 99.19 13.88 ± 2.83 262.50 ±  5.46 
GST30 30 94.23 12.90 ± 1.89 163.34 ±  7.12 
a Mean ± SD, b n=3, c n=50. 
 
Discrete, spherical and free flowing 
microparticles were obtained using 10, 15, and 
20 ml of the cross-linking agent. Batches GST25 
and GST30  which were cross-linked with 25 and 
30 ml of GST respectively, yielded irregular 
microparticles. The results presented in Table 1 
show that the microparticle yield (percentage 
yield) was high. Particularly noteworthy is the 
batch that had the highest yield of 99.19 %. This 
occurred in microparticles cross-linked with 25 ml 
of GST. Microparticles cross-linked with 15 ml of 
GST had the lowest yield (69.27 %). The results 
of the water sorption studies are shown in Figs. 1 
and 2. It can be seen from these figures that 
water sorption for all batches of the 
microparticles was higher in SIF than in SGF. 
Microparticles cross-linked with 25 ml of GST 
showed the highest degree of swelling  in SIF 
where 122.2 % water sorption was recorded 
when compared to that prepared with 10 ml GST 
which showed a water sorption of 42.6 %. Water 
sorption for microparticles cross-linked with 30 ml 
GST was, however, lower compared to that 
cross-linked with 25 ml GST. In SGF, the highest 
water sorption capacity was shown by 
microparticles cross-linked with 25 ml of GST 
and this was closely followed by microparticles 
cross-linked with 30 ml of GST. Approximately 
equal water sorption values were obtained for 
microparticles cross-linked with 10 and 20 ml of 
GST. Water absorption and the rate of water 
absorption by the microparticles followed the 
order: GST25 > GST30 > GST20 > GST15 > GST10 
in SIF while the order in SGF is: GST15 > GST30 
> GST25 > GST20 = GST10. It is discernible from 
Table 1 that the entrapment efficiency of all 
batches of the microparticles was in the range of 
12.90 ± 1.89 %   to 23.32 ± 0.97 % with 
microparticles cross-linked with 10 ml GST 
recording the highest drug entrapment. The 
general pattern was that drug entrapment 
decreased with increasing proportions of the 
cross-linking agent used in preparing the 
microparticles. Microparticles cross-linked with 
10 ml GST entrapped greater amounts (p ≤ 0.05) 
of ibuprofen in comparison with those cross-
linked with 30 ml of GST.  
 
 
Figure 1: Swelling profiles of iboprofen microparticles 
in SIF. Key: GST 10 (♦), GST 15 (■), GST 20 (▲), 
GST 25 (●), GST 30 (∆) 
 
 
Figure 2: Swelling profiles of ibuprofen microparticles 
in SGF. Key: GST 10 (V), GST 15 (V), GST 20 (V), 
GST 25 (V), GST 30 (V). 
 
The release profiles of ibuprofen from the 
microparticles in SIF and SGF are graphically 
represented in Figs 3 and 4. There was a 
sustained release of the drug from most of the 
microparticles. However, drug release was 
higher in SIF than in SGF, and there was an 
initial rapid release of ibuprofen from the 
microparticles cross-linked with 20 and 30 ml 
GST within 3 and 2 h, respectively in SIF. A 
characteristic feature of the release profile of 
ibuprofen from the latter batches of 
microparticles in SIF is the biphasic pattern of 
release. 
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Drug release in SIF was highest and more 
gradual and sustained from microparticles cross-
linked with 25 ml of GST where up to 93.6 % of 
the drug was released within 10 h. In SGF, the 
release of ibuprofen from the microparticles was 
lower and more gradual than in SIF. Drug 
release from the microparticles in SIF followed 
the order: GST25 > GST20  > GST30 > GST10  > 
GST15  while the order in SGF is: GST20 > GST30  
> GST10 > GST15  > GST25 . 
 
Table 2: Higuchi release kinetic parameters of 






Release parameter  
                      SIF                      SGF 




GST10 6.893 0.940 5.734 0.894 
GST15 5.322 0.817 3.273 0.944 
GST20 13.930 0.870 5.682 0.903 
GST25 11.930 0.840 3.190 0.737 
GST30 11.560 0.850 5.061 0.937 
KH = Higuchi release rate constant; r





Figure 3: Release profiles of ibuprofen from the 
microparticles in SIF. GST 10 (♦), GST 15 (■), GST 20 




The sizes of the microparticles were all within the 
micrometer range, indicating that the production 
process was able to achieve the intended end-
point. It  would appear that the average size of 
the microparticles increased with an increase in 
the proportion of the cross-linking agent 
employed. 
 
However, the microparticles cross-linked with 15 
ml of GST had a larger size than the other 
batches, especially microparticles cross-linked 
with 20, 25 and 30 ml GST possibly owing to 
incomplete cross-linking of the microparticles.   
 
 
Figure 4: Release profiles of ibuprofen from the 
microparticles in SGF: GST 10 (♦), GST 15 (■), GST 
20 (▲), GST 25 (●), GST 30 (∆) 
     
The microparticles evaluated in this study are 
intended for oral administration and particle size 
would influence the rate of drug release and 
subsequent pharmacokinetics [12]. The 
microparticle yield was high, an indication that 
the formulation technique adopted was reliable. 
There was no evidence of correlation between 
the proportion of cross-linking agent used in the 
formulation of microparticles and the 
microsphere yield. . Factors that influence 
swelling of swellabe polymers prepared by cross-
linking technique include the cross-linking time 
and the concentration of the cross-linking agent. 
Cross-linked chitosan is relatively stable in acidic 
medium but rapidly swells and releases its 
encapsulated drug in an alkaline medium [13-16]. 
By implication, encapsulation of ibuprofen in GST 
cross-linked chitosan microparticles would cause 
a little amount of the drug to be released in the 
stomach thereby decreasing its corrossive 
effects on the gastric mucosa and would further 
enhance its targeting to the intestine, where the 
desired sustained release effects would be 
achieved. It is equally clear from the results of 
the swelling studies that microparticles cross-
linked with 10 ml of GST had the lowest water 
sorption capacity in the two media. This may 
likely be the optimum amount of the cross-linking 
agent needed to produce microparticles for 
sustained release dosage form. Conversely, 
batch GST25 which was cross-linked with 25 ml 
of the cross-linking agent sustained the release 
of ibuprofen to the highest degree. 
 
The drug entrapment efficiency is an important 
variable for assessing the drug loading capacity 
of microparticles and their drug release profiles, 
thus suggesting that the amount of drug that 
would be available at the site of absorption. This 
Ofokansi et al.doc 
Trop J Pharm Res, February 2013;12 (1): 
 
24
parameter is dependent on the process of 
preparation, physicochemical properties of drug, 
and formulation variables [17-19]. The drug 
entrapment efficiency was observed to be 
dependent on the amount of cross-linking agent 
used in preparing the microparticles. 
Microparticles cross-linked with 10 ml of GST 
had higher mean drug content and thus higher 
loading efficiency compared to the drug content 
of microparticles cross-linked with 30 ml GST 
(Table 1). This was the optimum amount of 
cross-linking agent for formulation of chitosan 
microparticles using a cross-linking time of 2 h. 
This batch showed lower rate and degree of 
swelling than the other batches. Higher degree of 
swelling weakens secondary bonds in polymers 
and, thus, the lower degree of swelling in batch 
GST10 microparticles may have resulted in 
stronger attachment of the drug within the 
chitosan matrix. In addition, the wide variation in 
the drug contents of the different batches of the 
microparticles could be a consequence of the 
varying degrees of drug sedimentation and the 
relative partitioning of ibuprofen between the 
dispersed and continuous phases of the 
emulsion prior to cross-linking of the polymer 
[20]. 
 
The results depicted in Figs 4 and 5 indicate that 
the percentage drug released is highly 
dependent on the pH of the release media and 
the proportion of the cross-linking agent. The 
rapid release of ibuprofen from batches GST20 
and GST30  in the first 30 min is possibly due to a 
burst effect caused by the leaching out of the 
unentrapped drug adhering to the surface of the 
microparticles after the initial rapid hydration and 
swelling. Burst release resulting in biphasic 
release pattern may be utilized in therapeutic 
design of dosage forms. This has been observed 
in microparticles prepared using chitosan as a 
polymer [4,21]. There is a lot of peripheral 
attachment of the drug as a result of expulsion 
during microsphere drying (elastic contraction as 
seen in gels) or drug migration as a result of 
solvent drag during drying. In this case, however, 
this may be an advantage because it would lead 
to a high initial blood concentration of the drug 
and a gradual release of the remaining drug. In 
arthritis and chronic pain management, the 
objective is always to instantly alleviate pain and 
inflammatory conditions. This is possible if a 
bolus dose of the NSAID (ibuprofen) is 
administered. The bolus dose, when required, 
would be provided by the initial burst as seen in 
batches GST20 and GST30. The high and rapid 
release of ibuprofen from the microparticles in 
SIF, in addition to the burst effect, may also be a 
result of the high rate of hydration and swelling of 
the microparticles in SIF, which, in turn, could be 
attributable to the properties of the polymer 
(chitosan) used in preparing the microparticles. 
The subsequent slow release phase could be a 
consequence of the decreasing residual amount 
of drug in the microparticles and the build-up of 
drug concentration in the dissolution medium in 
the course of time. This indicates that once the 
drug adhering to the microspheric surface has 
leached, the drug release becomes diffusion-
controlled. Moreover, chitosan possesses 
bioadhesive properties [22,23]. This is an added 
advantage since the transit time of the dosage 
form would be prolonged in the gastrointestinal 
tract for maximum absorption of the active 
ingredient. Further kinetic analysis of the release 
data was performed on the ibuprofen-loaded 
chitosan microparticles. The criterion was based 
on a goodness-of-fit test. The result of the 
different parameters derivable from the Higuchi 
release model [24] is presented in Table 2. The 
values show that batch GST10 microparticles 
obeyed the Higuchi membrane diffusion-
controlled model in SIF, whereas batches GST15 
and GST20 microparticles followed the model in 
SGF and thus exhibited diffusion-controlled 
release. The implication is that cross-linking the 
microparticles with 10 ml of GST increased the 
diffusional tendency of the incorporated drug in 
SIF. Similarly, cross-linking the chitosan 
microparticles with 15  and 20 ml of GST 





Ibuprofen-loaded microparticles were 
successfully prepared using medium molecular 
weight chitosan by the emulsification-solvent 
evaporation technique using glutaraldehyde 
saturated toluene as the cross-linking agent. 
Glutaraldehyde cross-linked medium molecular 
weight chitosan could be useful in controlling the 
release of ibuprofen with a potential of reducing 
its gastrointestinal side effects and dosing 
frequency. Further studies would seek to 
evaluate these formulations by employing 
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